Figure 3.
Outcome of E2993 molecular subgroups. Kaplan-Meier estimates for RFS and OS of molecular subgroups included in the outcome analysis. The RFS analysis included only patients who achieved a complete remission (DUX4-R, 18 patients; TCF3-PBX1, 12; PAX5 P80R, 9; Hyperdiploid, 15; ETV6-RUNX1/-like, 5; ZNF384-R/-like, 10; PAX5alt, 24; MEF2D-R, 6; KMT2A-AFF1, 21; Ph-like, 41; Hypodiploid/Haploid, 24; BCL2/MYC, 3). The OS analysis included all patients with outcome information (DUX4-R, 20 patients; TCF3-PBX1, 15; PAX5 P80R, 9; Hyperdiploid, 15; ETV6-RUNX1/-like, 5; ZNF384-R/-like, 11; PAX5alt, 27; MEF2D-R, 6; KMT2A-AFF1, 26; Ph-like, 46; Hypodiploid/Haploid, 31; BCL2/MYC, 6). Among DUX4-R, ETV6-RUNX1/-like, TCF3-PBX1, PAX5 P80R, and hyperdiploid patients, neither RFS nor OS varied significantly.

Outcome of E2993 molecular subgroups. Kaplan-Meier estimates for RFS and OS of molecular subgroups included in the outcome analysis. The RFS analysis included only patients who achieved a complete remission (DUX4-R, 18 patients; TCF3-PBX1, 12; PAX5 P80R, 9; Hyperdiploid, 15; ETV6-RUNX1/-like, 5; ZNF384-R/-like, 10; PAX5alt, 24; MEF2D-R, 6; KMT2A-AFF1, 21; Ph-like, 41; Hypodiploid/Haploid, 24; BCL2/MYC, 3). The OS analysis included all patients with outcome information (DUX4-R, 20 patients; TCF3-PBX1, 15; PAX5 P80R, 9; Hyperdiploid, 15; ETV6-RUNX1/-like, 5; ZNF384-R/-like, 11; PAX5alt, 27; MEF2D-R, 6; KMT2A-AFF1, 26; Ph-like, 46; Hypodiploid/Haploid, 31; BCL2/MYC, 6). Among DUX4-R, ETV6-RUNX1/-like, TCF3-PBX1, PAX5 P80R, and hyperdiploid patients, neither RFS nor OS varied significantly.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal